Boundless Bio Presents Preclinical Data for BBI-940 at AACR Annual Meeting 2026
Boundless Bio presents preclinical data supporting its lead ecDNA-directed therapy, BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, a potentially first-in-class, oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. "Extrachromosomal DNA is well established as a distinct enabler of chromosomal instability associated with oncogene amplification, therapeutic resistance, and poor outcomes for patients," said Chris Hassig, Chief Scientific Officer. "We have discovered and validated a novel kinesin target that plays a critical role in ecDNA segregation during cell division, thereby affording tumors with a high degree of genomic plasticity. Our data demonstrate that selective degradation of this target delivered potent antitumor activity in validated breast cancer models, particularly those with ecDNA. Our genetic, in vitro, in vivo, and toxicity profile of BBI-940 supports our recently initiated, first-in-human KOMODO-1 clinical trial evaluating BBI-940 in ER+/HER2- and TNBC-LAR breast cancer patients."
Trade with 70% Backtested Accuracy
Analyst Views on BOLD
About BOLD
About the author
Boundless Bio to Present Preclinical Data on BBI-940 at AACR Annual Meeting 2026
- Clinical Data Presentation: Boundless Bio announced it will present preclinical data on its lead therapy BBI-940 at the 2026 American Association for Cancer Research Annual Meeting, targeting advanced or metastatic breast cancer patients, showcasing its potential in cancer treatment.
- FDA Application Approval: In January 2026, the U.S. FDA accepted the Investigational New Drug application for BBI-940, marking a significant advancement in the clinical development of this therapy and potentially accelerating its path to market.
- Mechanism Research Findings: Studies indicate that genetic and pharmacological degradation of Kinesin leads to ecDNA mis-segregation and depletion, thereby reducing the viability of ecDNA+ cancer cells, providing a novel therapeutic strategy for high-risk cancers.
- Strong Financial Position: As of December 31, 2025, Boundless Bio reported cash and cash equivalents totaling $107.6 million, expected to fund operations into the second half of 2028, demonstrating the company's ongoing investment capability in R&D.
Boundless Bio Presents Preclinical Data for BBI-940 at AACR 2026
- Preclinical Data Presentation: Boundless Bio showcased preclinical data for its lead ecDNA-directed therapy BBI-940 at the 2026 AACR Annual Meeting, indicating its potential as a first-in-class oral selective Kinesin degrader for treating intractable tumors.
- Target Discovery: The research team identified a novel Kinesin target essential for ecDNA segregation and inheritance in cancer cells but non-essential in healthy cells, laying the groundwork for developing new therapies targeting ecDNA-positive tumors.
- Clinical Trial Progress: BBI-940 is currently undergoing the first-in-human Phase 1 KOMODO-1 clinical trial for patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR, with preliminary results showing promising antitumor activity across multiple tumor types.
- Market Potential: With 14% to 17% of cancer patients exhibiting ecDNA amplification, the development of BBI-940 not only addresses significant unmet medical needs but also positions Boundless Bio for a strategic advantage in the competitive oncology market.
Boundless Bio Q4 Earnings Miss Expectations
- Earnings Performance: Boundless Bio reported a Q4 GAAP EPS of -$0.58, missing expectations by $0.12, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $107.6 million in cash, cash equivalents, and short-term investments, reflecting a solid liquidity position in the short term, though long-term sustainability remains a concern.
- Operational Funding Outlook: The company expects its cash reserves to fund operations into the second half of 2028, coinciding with the anticipated initial clinical proof-of-concept readout from KOMODO-1, which is crucial for future growth prospects.
- Market Reaction Expectations: Given the earnings miss, investors may express concerns regarding the company's future clinical trials and cash utilization plans, potentially impacting stock performance and market confidence.
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
Boundless Bio to Present Preclinical Data on BBI-940 at AACR Annual Meeting 2026
- Clinical Data Presentation: Boundless Bio announced it will present preclinical data on its lead therapy BBI-940 at the 2026 American Association for Cancer Research Annual Meeting, targeting advanced or metastatic breast cancer patients, showcasing its potential in cancer treatment.
- FDA Application Approval: In January 2026, the U.S. FDA accepted the Investigational New Drug application for BBI-940, marking a significant advancement in the clinical development of this therapy and potentially accelerating its path to market.
- Mechanism Research Findings: Studies indicate that genetic and pharmacological degradation of Kinesin leads to ecDNA mis-segregation and depletion, thereby reducing the viability of ecDNA+ cancer cells, providing a novel therapeutic strategy for high-risk cancers.
- Strong Financial Position: As of December 31, 2025, Boundless Bio reported cash and cash equivalents totaling $107.6 million, expected to fund operations into the second half of 2028, demonstrating the company's ongoing investment capability in R&D.
Boundless Bio Presents Preclinical Data for BBI-940 at AACR 2026
- Preclinical Data Presentation: Boundless Bio showcased preclinical data for its lead ecDNA-directed therapy BBI-940 at the 2026 AACR Annual Meeting, indicating its potential as a first-in-class oral selective Kinesin degrader for treating intractable tumors.
- Target Discovery: The research team identified a novel Kinesin target essential for ecDNA segregation and inheritance in cancer cells but non-essential in healthy cells, laying the groundwork for developing new therapies targeting ecDNA-positive tumors.
- Clinical Trial Progress: BBI-940 is currently undergoing the first-in-human Phase 1 KOMODO-1 clinical trial for patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR, with preliminary results showing promising antitumor activity across multiple tumor types.
- Market Potential: With 14% to 17% of cancer patients exhibiting ecDNA amplification, the development of BBI-940 not only addresses significant unmet medical needs but also positions Boundless Bio for a strategic advantage in the competitive oncology market.
Boundless Bio Q4 Earnings Miss Expectations
- Earnings Performance: Boundless Bio reported a Q4 GAAP EPS of -$0.58, missing expectations by $0.12, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $107.6 million in cash, cash equivalents, and short-term investments, reflecting a solid liquidity position in the short term, though long-term sustainability remains a concern.
- Operational Funding Outlook: The company expects its cash reserves to fund operations into the second half of 2028, coinciding with the anticipated initial clinical proof-of-concept readout from KOMODO-1, which is crucial for future growth prospects.
- Market Reaction Expectations: Given the earnings miss, investors may express concerns regarding the company's future clinical trials and cash utilization plans, potentially impacting stock performance and market confidence.
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
